title: Reply to the comment from Bjerre et al.
authors: Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, Suzhou, China.
authors: Xiao-Liang
authors: XL
authors: Ding
authors: Zhi-Yao
authors: ZY
authors: Chen
authors: Cheng
authors: C
authors: Xie
authors: Li-Yan
authors: LY
authors: Miao
mesh_terms: D002265:Carboxylic Ester Hydrolases / Q000235:genetics*; D003327:Coronary Disease / Q000628:therapy*; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D013988:Ticlopidine / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; D065731:Cytochrome P-450 CYP2C19; D002265:Carboxylic Ester Hydrolases; D013988:Ticlopidine